ClearPoint Neuro, Inc. (CLPT) has a negative trailing P/E of -9.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -10.10%.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.2 | 0.03 | -12.39 | 1.63 | - |
| 2017 | -3.0 | 0.04 | 3.65 | 2.88 | - |
| 2018 | -2.8 | 0.07 | 11.35 | 2.33 | - |
| 2019 | -11.4 | 0.91 | 13.77 | 5.63 | - |
| 2020 | -37.1 | 3.03 | 105.95 | 19.63 | - |
| 2021 | -16.1 | -0.27 | 4.77 | 14.27 | - |
| 2022 | -12.5 | 8.60 | 5.55 | 9.97 | - |
| 2023 | -7.6 | -0.23 | 7.89 | 6.97 | - |
| 2024 | -22.0 | 0.99 | 16.37 | 13.24 | - |
| 2025 | -15.2 | -0.53 | 13.82 | 10.48 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.93 | $5.75M | $-8.07M | -140.4% |
| 2017 | $-0.93 | $7.38M | $-7.17M | -97.1% |
| 2018 | $-0.56 | $7.35M | $-6.16M | -83.8% |
| 2019 | $-0.49 | $11.22M | $-6.5M | -58% |
| 2020 | $-0.57 | $12.83M | $-9.11M | -71% |
| 2021 | $-0.74 | $16.3M | $-15.32M | -94% |
| 2022 | $-0.68 | $20.55M | $-16.54M | -80.5% |
| 2023 | $-0.90 | $23.96M | $-22.09M | -92.2% |
| 2024 | $-0.70 | $31.39M | $-18.91M | -60.3% |
| 2025 | $-0.90 | $36.97M | $-25.54M | -69.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.97 | $-0.99 – $-0.95 | $52.8M | $51.93M – $53.67M | 1 |
| 2027 | $-0.82 | $-0.83 – $-0.80 | $63.1M | $62.06M – $64.14M | 1 |
